Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.90 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.90 |
| ▸ | ESRRG | P62508 | 6/20 | 0.90 |
| ▸ | MAPT | P10636 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | ESRRB | O95718 | 3/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | TP53 | P04637 | 2/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | PGR | P06401 | 2/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.90 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.90 |
| ▸ | PLD2 | O14939 | 1/20 | 0.90 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.90 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9857837 | 1.00 | ESR1 (0.90) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL9857247 | 1.00 | ESR1 (0.90) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL15668666 | 0.95 | ESR1 (1.00) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL2165503 | 0.95 | ESR1 (1.00) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Afimoxifene SCHEMBL640496 | 0.95 | ESR1 (1.00) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL7799603 | 0.95 | ESR1 (0.81) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL10828052 | 0.95 | ESR1 (0.81) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL10827999 | 0.95 | ESR1 (0.81) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Afimoxifene SCHEMBL9189 | 0.95 | ESR1 (1.00) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Afimoxifene SCHEMBL2132301 | 0.95 | ESR1 (1.00) | ESR1ESR2ESRRGMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0272330-B1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1991-05-22 | — | — | EP | claimed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| EP-3778590-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | ShanghaiTech University (CN) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778590-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | ShanghaiTech University (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019196812-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | 上海科技大学 | 2019-10-17 | — | — | WO | disclosed |
| WO-2012119010-A9 | MATERIALS FOR INHIBITING AROMATASE AND METHOD OF USING THE SAME TO DIAGNOSE, TREAT AND MONITOR BREAST CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012119010-A9 | MATERIALS FOR INHIBITING AROMATASE AND METHOD OF USING THE SAME TO DIAGNOSE, TREAT AND MONITOR BREAST CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012119010-A3 | MATERIALS FOR INHIBITING AROMATASE AND METHOD OF USING THE SAME TO DIAGNOSE, TREAT AND MONITOR BREAST CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012119010-A2 | MATERIALS FOR INHIBITING AROMATASE AND METHOD OF USING THE SAME TO DIAGNOSE, TREAT AND MONITOR BREAST CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012119010-A2 | MATERIALS FOR INHIBITING AROMATASE AND METHOD OF USING THE SAME TO DIAGNOSE, TREAT AND MONITOR BREAST CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-0272330-B1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-4897503-A | ANTITUMOR AGENTS; TREATING MAMMARY CANCER AND ANOVULATORY INFERTILITY | TAIHO PHARMACEUTICAL (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0272330-A1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | ESR1 2864/4885ESR2 1256/4885ESRRG 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.